SMO and demyelinating disease: Regarding safety issues for GCs used in the clinic, although FGCs acting as Smo agonists are suggested for the treatment of neovascularization after myocardial infarction [64], neuronal degeneration after spinal cord injury [65], and wound healing in diabetes [66], we are not aware of data regarding their use for demyelinating diseases in the clinic.